Maelstrom Research Staging | ICoVVaC_CohortA_12months

ICoVVaC_CohortA_12months_postdose3

Networks -

Variables -

Associated study ICoVVaC Contingency Table

Population

ICoVVaC - Cohort A

The population is composed of healthy subjects who at first were not vaccinated but are receiving COVID-19 vaccination as part of the national vaccine roll-out (standard of care) and included in the study within 4 weeks of the second dose of vaccine.

Selection Criteria

Minimum age

Newborns

Twins

Countries

Canada

Territory

Ottawa

Ethnic Origin

Health Status

Healthy

Other Criteria

Inclusion: Patients who will be receiving COVID-19 vaccination and are within 4 weeks of the second dose of vaccine

Recruitment

Sources of recruitment

General population

General Population

Volunteer enrolment

Supplementary Information

Participants were recruited by self-referral, or after receiving promotion of study through social media (Twitter, Facebook), or visiting the cancer centre and hospital (where posters about the study are displayed).

Number of Participants

Number of Participants: 72
Number of Participants with Biological Samples: 72

More info

Data Collection Event

ICoVVaC - Cohort A - 12 months post-dose 3

Information on vaccine information and assessment of clinical outcomes (incidence of COVID-19) was collected. Blood (serum and peripheral blood mononuclear cells (PBMCs) samples were collected.

More info

Collected Dataset / ICoVVaC_CohortA_12months_postdose3

ICoVVaC_CohortA_12months_postdose3

Population

ICoVVaC - Cohort A

Data Collection Event

ICoVVaC - Cohort A - 12 months post-dose 3

Files

Variables Classifications